Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics Announces Publication of Preclinical Data Supporting Rigosertib’s Mechanism of Action as a Targeted Anticancer Therapy
July 23, 2020 08:00 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., July 23, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics Announces Publication of Phase 1 Results in Leukemia Research Exploring Oral Rigosertib in Combination with Azacitidine in Higher-Risk MDS
July 07, 2020 08:00 ET | Onconova Therapeutics, Inc.
RAS-focused mechanism of action and manageable side effect profile indicate potential promise for oral rigosertib as part of future combination therapies NEWTOWN, Pa., July 07, 2020 (GLOBE...
Geron-logo-black-xsmall.png
Geron Receives Positive Opinion from the EMA Committee for Orphan Medicinal Products for Orphan Drug Designation in the European Union for Imetelstat to Treat Myelodysplastic Syndromes
July 01, 2020 08:30 ET | Geron Corporation
Designation would provide 10-year period of marketing exclusivity in the European Union after product approvalPatients are currently enrolling in a Geron-sponsored Phase 3 clinical trial in lower risk...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics Announces Participation in Noble Capital Markets Investor Webinar
June 23, 2020 08:00 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., June 23, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...
Geron-logo-black-xsmall.png
Geron Reports Four Imetelstat Data Presentations at Virtual Edition of the European Hematology Association (EHA) Annual Congress
June 12, 2020 08:30 ET | Geron Corporation
For the IMerge Phase 2 clinical trial, meaningful and durable transfusion independence reported with a new 1-year TI rate, indicating potential disease-modifying activity of imetelstat treatmentFor...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics Announces Presentation at the 25th Congress of the European Hematology Association (EHA)
June 12, 2020 08:00 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., June 12, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...
Aprea logo 445pt.png
Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 (Eprenetapopt) and Azacitidine in Patients with TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia at the 25th European Hematology Association Annual Meeting
June 12, 2020 06:00 ET | Aprea Therapeutics
57% CR and 75% ORR rate by IWG criteria in all evaluable MDS patients 12.1 months median OS in intention-to-treat MDS patients with 9.7 months median duration of follow-up 13.7 months median OS...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics Announces Presentation at BIO Digital 2020
June 08, 2020 08:00 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., June 08, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...
Aprea logo 445pt.png
Aprea Therapeutics Completes Full Enrollment of Phase 3 Clinical Trial in TP53 Mutant Myelodysplastic Syndromes (MDS)
June 03, 2020 08:00 ET | Aprea Therapeutics
Topline data expected by year-end 2020Applications for US and EU regulatory approval planned for 2021 BOSTON, June 03, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a...
Geron-logo-black-xsmall.png
Geron Corporation Reports First Quarter 2020 Financial Results
May 28, 2020 16:05 ET | Geron Corporation
MENLO PARK, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the first quarter ended March 31, 2020. The Company will host a conference...